As GINA is Signed Into Law, Most Predict Great Gains, But Some See Shortcomings, Others Find a Mixed Bag
By John T. Aquino,
The Bureau of National Affairs
| 06. 05. 2008
[Quotes CGS's Marcy Darnovsky]
President Bush May 21 signed into law the Genetic Information
Nondiscrimination Act, which prohibits employers, health plans, and
insurers from discriminating against individuals on the basis of
genetic information. The new law was applauded by lawmakers of both
parties and by health-related groups. After the signing, however, some
individuals and organizations, while acknowledging up-front benefits,
began to suggest that, long term, the new law might lead to loss of
privacy and threaten biopharmaceutical research and intellectual
property. Others discounted those fears, predicting the industries
will be strengthened not harmed.
The Genetic Information Nondiscrimination Act (GINA), which was
introduced in Congress six times in various forms over the last 12
years and passed twice by the Senate but not by the House of
Representatives, was approved unanimously by the Senate April 24 and
on a vote of 414-1 by the House May 1 (2 LSLR 373, 5/9/08). The new
law (Pub. L. No. 110-233) aims to eliminate any fear of discrimination
by those who undergo genetic testing and thus encourage people to have
these potentially beneficial tests. The law amends the...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...